{"0": {"chronic lymphocytic": 0.7206695079803467, "lymphocytic leukemia": 0.6662033200263977, "lymphocytic leukaemia": 0.6592550277709961, "leukemia hematology": 0.5637084245681763, "lymphocytic": 0.5568845272064209, "lymphocytes": 0.5451659560203552, "lymphocyte": 0.5428459644317627, "follicular lymphoma": 0.5045711398124695, "small lymphocytic": 0.4971219301223755, "leukemia": 0.494589626789093, "lymphocyte count": 0.48154962062835693, "swollen lymph": 0.4654470682144165, "enlarged lymph": 0.45425790548324585, "lymphoma": 0.4489077031612396, "hematologic malignancies": 0.4138631820678711, "refractory chronic": 0.4077634811401367, "patients with chronic": 0.39653441309928894, "cell therapy": 0.39384037256240845, "tumor lysis": 0.39243337512016296, "lymph nodes": 0.38978156447410583, "leukaemia": 0.3883655369281769, "cell malignancies": 0.3875350058078766, "disease progression": 0.3723292052745819, "chronic": 0.3651652932167053, "lymph": 0.35198426246643066, "cancer therapy": 0.34870442748069763, "hematologic": 0.34865903854370117, "blood cancer": 0.34265363216400146, "blood cancers": 0.3364924192428589, "cell transplant": 0.33588987588882446, "immunotherapy": 0.33398082852363586, "hematology": 0.32013043761253357, "smudge cells": 0.3162083625793457, "hematologist": 0.31145143508911133, "hematologist oncologist": 0.30538859963417053, "cancer": 0.29976749420166016, "disease": 0.29545319080352783, "hematology advisor": 0.29278770089149475, "cancer survivors": 0.2922021150588989, "cells": 0.28903794288635254, "tumor": 0.2881975471973419, "cancers": 0.28209996223449707, "chemotherapy free": 0.26148831844329834, "chemotherapy": 0.25932955741882324, "cell": 0.25610098242759705, "cancer network": 0.24826663732528687, "cancer center": 0.24722424149513245, "fixed duration": 0.23441635072231293, "newly diagnosed": 0.2289876639842987, "flow cytometry": 0.2287319302558899}, "1": {"dr byrd": 0.42932382225990295, "dr abedin": 0.4228556752204895, "refractory cll": 0.4117785394191742, "dr woyach": 0.4028850793838501, "btk inhibitors": 0.39634969830513, "btk inhibitor": 0.3947063386440277, "dr wierda": 0.3870282769203186, "dr": 0.38457977771759033, "dr danilov": 0.3799437880516052, "dr davids": 0.3659256100654602, "btk inhibition": 0.3633077144622803, "covid vaccine": 0.3497816324234009, "hematology advisor": 0.344190776348114, "refractory chronic": 0.3415612578392029, "chronic lymphocytic": 0.3400629758834839, "acalabrutinib demonstrates": 0.3356560468673706, "venetoclax obinutuzumab": 0.3355223536491394, "dr mato": 0.3354111909866333, "dr brander": 0.3349403738975525, "patients with chronic": 0.3245657682418823, "cll": 0.32348090410232544, "dr ghia": 0.3222367465496063, "umbralisib ublituximab": 0.3191284239292145, "pi inhibitors": 0.30883318185806274, "cll sll": 0.3006775677204132, "dr shadman": 0.299954891204834, "my doc": 0.29750362038612366, "doc": 0.29641321301460266, "my doctor": 0.28736627101898193, "lymphocytic leukaemia": 0.2854532301425934, "chronic": 0.2820775806903839, "hematologist oncologist": 0.2810831069946289, "medicare": 0.27836066484451294, "doctor": 0.2774897813796997, "venetoclax based": 0.2722935378551483, "clinical trial": 0.26921015977859497, "oncologist": 0.26671409606933594, "leukemia hematology": 0.2642033100128174, "lymphocyte count": 0.2639004588127136, "inhibitor": 0.26119205355644226, "relapsed refractory": 0.2593859136104584, "hematologic malignancies": 0.25746890902519226, "hematologist": 0.2564351558685303, "lymphocytic leukemia": 0.2561829090118408, "drug": 0.25178760290145874, "therapeutics announces": 0.2517157196998596, "inhibitors": 0.2509363293647766, "follicular lymphoma": 0.2453390657901764, "lymphocytic": 0.2448427677154541, "clinical trials": 0.24462799727916718}, "2": {"targeted therapies": 0.5569481253623962, "treatment options": 0.5488420724868774, "treatment paradigm": 0.537477433681488, "tg therapeutics": 0.5370941162109375, "targeted therapy": 0.5348566174507141, "therapeutics announces": 0.5203647613525391, "treatment naive": 0.519433856010437, "treatment": 0.5136090517044067, "combination therapies": 0.5006380081176758, "combination therapy": 0.5005282163619995, "chemotherapy": 0.49718716740608215, "chemotherapy free": 0.4940451681613922, "therapeutic": 0.489757239818573, "cell therapy": 0.4854027330875397, "treatments": 0.4797954261302948, "therapies": 0.4770908057689667, "therapeutics": 0.4744284152984619, "cancer therapy": 0.4729292392730713, "therapy": 0.46772533655166626, "immunotherapy": 0.44932788610458374, "previously treated": 0.4343562722206116, "treating": 0.42201006412506104, "patients with chronic": 0.41206303238868713, "treated": 0.4102824032306671, "treatment landscape": 0.4090038537979126, "cure": 0.40666663646698, "monotherapy": 0.3881058394908905, "previously untreated": 0.37314918637275696, "refractory cll": 0.3716278672218323, "refractory chronic": 0.3446284234523773, "medicare": 0.3374480605125427, "hematology advisor": 0.33123043179512024, "clinical trial": 0.32696378231048584, "treat": 0.3256034553050995, "covid vaccine": 0.3251437246799469, "clinical": 0.32429227232933044, "untreated": 0.3183852732181549, "chronic lymphocytic": 0.309717059135437, "oncologist": 0.30662840604782104, "clinical trials": 0.3062881529331207, "hematologist oncologist": 0.30103522539138794, "cll": 0.2852214276790619, "chronic": 0.279348224401474, "newly diagnosed": 0.27567771077156067, "dr byrd": 0.2714712917804718, "medical": 0.2685399353504181, "transplant": 0.2627917230129242, "dr abedin": 0.26244795322418213, "disease progression": 0.2615912854671478, "hematologist": 0.25946834683418274}, "3": {"cancer therapy": 0.6259983777999878, "cancer survivors": 0.4898570775985718, "cancer": 0.4827738404273987, "chemotherapy": 0.4825426936149597, "blood cancer": 0.4811170995235443, "blood cancers": 0.47344154119491577, "chemotherapy free": 0.4731505513191223, "cancers": 0.462114155292511, "tumor lysis": 0.447301983833313, "cancer network": 0.4468904137611389, "cancer center": 0.4234839677810669, "immunotherapy": 0.4098619818687439, "cell therapy": 0.4040030837059021, "lymphocytic leukaemia": 0.4036492705345154, "leukemia hematology": 0.39409011602401733, "tumor": 0.39060306549072266, "lymphocytic leukemia": 0.37947195768356323, "chronic lymphocytic": 0.36717820167541504, "hematologic malignancies": 0.35875025391578674, "hematology advisor": 0.3574337959289551, "targeted therapies": 0.3564383387565613, "covid vaccine": 0.3508998155593872, "hematologist oncologist": 0.346710741519928, "therapeutics announces": 0.34363478422164917, "leukemia": 0.3361493647098541, "treatment naive": 0.33365026116371155, "patients with chronic": 0.32419371604919434, "tg therapeutics": 0.3215647339820862, "targeted therapy": 0.3204038441181183, "combination therapies": 0.30809977650642395, "treatment": 0.30536943674087524, "therapies": 0.3050503432750702, "treatment paradigm": 0.29962843656539917, "cell malignancies": 0.29430514574050903, "combination therapy": 0.2935101091861725, "leukaemia": 0.2916736602783203, "oncologist": 0.28905946016311646, "treatment options": 0.28891733288764954, "cure": 0.2884153723716736, "treatments": 0.2862456142902374, "therapy": 0.28523969650268555, "hematologist": 0.28238773345947266, "therapeutic": 0.28032752871513367, "therapeutics": 0.2762061655521393, "previously treated": 0.2749393582344055, "disease progression": 0.2721812129020691, "vaccines": 0.2695789337158203, "vaccine": 0.26825475692749023, "small lymphocytic": 0.26646459102630615, "lymphocytes": 0.26290175318717957}, "4": {"chronic lymphocytic": 0.38678085803985596, "refractory chronic": 0.3729234039783478, "survival benefit": 0.33951154351234436, "venetoclax obinutuzumab": 0.3349761664867401, "acalabrutinib demonstrates": 0.3297267556190491, "improves pfs": 0.32738834619522095, "chronic": 0.3144564628601074, "prolongs pfs": 0.31146040558815, "patients with chronic": 0.30543267726898193, "refractory cll": 0.30289095640182495, "btk inhibitors": 0.3019980192184448, "btk inhibitor": 0.29481589794158936, "previously treated": 0.29190394282341003, "previously untreated": 0.2910805344581604, "lymphocytic leukaemia": 0.28055500984191895, "follicular lymphoma": 0.27726173400878906, "umbralisib ublituximab": 0.2713128924369812, "covid vaccine": 0.27061453461647034, "plus obinutuzumab": 0.2700807452201843, "lymphocytic": 0.26891767978668213, "lymphocytic leukemia": 0.2638925015926361, "plus venetoclax": 0.26265859603881836, "enlarged lymph": 0.2612974941730499, "disease progression": 0.2581661343574524, "benefit": 0.25691139698028564, "lymphocyte": 0.25298428535461426, "btk inhibition": 0.2524683177471161, "lymphocyte count": 0.24216243624687195, "sustained": 0.24089264869689941, "pi inhibitors": 0.23807553946971893, "lymphocytes": 0.23781149089336395, "ibrutinib plus": 0.23731955885887146, "small lymphocytic": 0.2350587397813797, "venetoclax based": 0.23412007093429565, "acalabrutinib shows": 0.2329842746257782, "acalabrutinib": 0.23158583045005798, "immunotherapy": 0.22854170203208923, "venetoclax": 0.2285333275794983, "benefits": 0.22813493013381958, "relapsed refractory": 0.2237706333398819, "fixed duration": 0.22147014737129211, "cll": 0.22145909070968628, "cirmtuzumab": 0.22072535753250122, "improves": 0.2201019823551178, "lymphoma": 0.21866317093372345, "favorable": 0.21718397736549377, "swollen lymph": 0.21715041995048523, "leukemia": 0.21632198989391327, "lymph nodes": 0.2146843820810318, "treatment naive": 0.21204930543899536}, "5": {"cell therapy": 0.6122380495071411, "car cells": 0.4790186285972595, "car cell": 0.4539434611797333, "cancer therapy": 0.42529553174972534, "targeted therapies": 0.4191262125968933, "chemotherapy": 0.4162105917930603, "cell transplant": 0.41219252347946167, "treatment naive": 0.4086412787437439, "targeted therapy": 0.4027916193008423, "chemotherapy free": 0.40242525935173035, "therapeutics announces": 0.39885449409484863, "immunotherapy": 0.3931129574775696, "tg therapeutics": 0.38572317361831665, "cell malignancies": 0.3783549666404724, "treatment": 0.3782551884651184, "treatment paradigm": 0.37255409359931946, "smudge cells": 0.36660245060920715, "chronic lymphocytic": 0.3605763912200928, "therapies": 0.355349600315094, "therapy": 0.354446679353714, "treatments": 0.3538265824317932, "therapeutic": 0.3485218286514282, "lymphocytic leukaemia": 0.3472921848297119, "lymphocytic leukemia": 0.3430367708206177, "treatment options": 0.3390694558620453, "cell": 0.3375856876373291, "therapeutics": 0.3360195755958557, "cells": 0.3295023441314697, "combination therapy": 0.32777225971221924, "combination therapies": 0.32606443762779236, "cure": 0.315604567527771, "lymphocytes": 0.3096607029438019, "previously treated": 0.30884310603141785, "monotherapy": 0.3013233244419098, "leukemia hematology": 0.29779142141342163, "lymphocyte count": 0.29036277532577515, "treating": 0.28909850120544434, "treated": 0.2882293462753296, "lymphocyte": 0.28579628467559814, "treatment landscape": 0.28336480259895325, "lymphocytic": 0.2794334590435028, "clinical trial": 0.2786344289779663, "patients with chronic": 0.27311915159225464, "leukemia": 0.26634031534194946, "clinical trials": 0.2661131024360657, "previously untreated": 0.26551803946495056, "clinical": 0.25968655943870544, "car": 0.252167284488678, "small lymphocytic": 0.24403297901153564, "disease progression": 0.23654970526695251}, "6": {"patients with chronic": 0.5502554178237915, "chronic lymphocytic": 0.43821972608566284, "lymphocytic leukaemia": 0.4270601272583008, "covid vaccine": 0.4148581624031067, "disease": 0.3923870027065277, "lymphocytic leukemia": 0.3809013366699219, "patients": 0.37591347098350525, "disease progression": 0.37231093645095825, "refractory cll": 0.3712710738182068, "refractory chronic": 0.37012025713920593, "leukaemia": 0.36307504773139954, "leukemia": 0.360537052154541, "hematologic malignancies": 0.35802116990089417, "leukemia hematology": 0.35173121094703674, "chronic": 0.350263774394989, "lymphocytic": 0.33867672085762024, "lymphocyte count": 0.33449724316596985, "younger patients": 0.3341391682624817, "older patients": 0.3224635422229767, "small lymphocytic": 0.32222598791122437, "lymphocyte": 0.3165974020957947, "cll": 0.3132592439651489, "swollen lymph": 0.31272637844085693, "follicular lymphoma": 0.3117148280143738, "lymphocytes": 0.3099140524864197, "patient": 0.302476704120636, "syndrome": 0.30083703994750977, "hematologic": 0.2985689043998718, "immunotherapy": 0.2967826724052429, "clinical": 0.2957613468170166, "cll sll": 0.2933054268360138, "tumor lysis": 0.2912819981575012, "vaccinated": 0.28352707624435425, "fully vaccinated": 0.2828702926635742, "was diagnosed": 0.2808340787887573, "vaccine": 0.2755807340145111, "clinical trials": 0.2753663659095764, "venetoclax obinutuzumab": 0.2738763391971588, "elderly patients": 0.27371707558631897, "clinical trial": 0.2735568881034851, "vaccines": 0.2731776237487793, "vaccination": 0.27282118797302246, "hematologist": 0.2716646194458008, "cell malignancies": 0.27004575729370117, "btk inhibitors": 0.26776525378227234, "hematology advisor": 0.26759567856788635, "blood cancers": 0.26658952236175537, "cancer survivors": 0.2665533423423767, "cancer": 0.2663215696811676, "cancers": 0.2661295235157013}, "7": {"treatment naive": 0.4762183427810669, "treatment": 0.46407270431518555, "cell therapy": 0.46183425188064575, "treatment paradigm": 0.4556952118873596, "immunotherapy": 0.4502559006214142, "targeted therapies": 0.4455866813659668, "tg therapeutics": 0.44379541277885437, "chemotherapy": 0.43508636951446533, "targeted therapy": 0.43161797523498535, "treatment options": 0.4282585382461548, "treatments": 0.4274772107601166, "chemotherapy free": 0.4219033122062683, "venetoclax obinutuzumab": 0.4197489321231842, "previously treated": 0.4193998873233795, "therapeutics announces": 0.41359829902648926, "combination therapy": 0.40943771600723267, "therapeutic": 0.4094146490097046, "combination therapies": 0.3946104049682617, "monotherapy": 0.39104408025741577, "cancer therapy": 0.389492392539978, "therapeutics": 0.38835930824279785, "therapies": 0.3862351179122925, "treated": 0.3778470754623413, "therapy": 0.37397056818008423, "chronic lymphocytic": 0.37142470479011536, "treating": 0.36737000942230225, "venetoclax based": 0.36292171478271484, "previously untreated": 0.35431694984436035, "refractory cll": 0.35164713859558105, "cure": 0.34960487484931946, "covid vaccine": 0.34307998418807983, "venetoclax": 0.33501383662223816, "treatment landscape": 0.3222782611846924, "refractory chronic": 0.31796663999557495, "plus venetoclax": 0.31411033868789673, "lymphocytic leukaemia": 0.3125535547733307, "patients with chronic": 0.30743569135665894, "lymphocytic": 0.305799275636673, "lymphocytic leukemia": 0.2918968200683594, "treat": 0.2910991907119751, "btk inhibitor": 0.28669828176498413, "btk inhibitors": 0.28282615542411804, "untreated": 0.2800542414188385, "lymphocyte": 0.2777253985404968, "lymphocyte count": 0.2753821313381195, "follicular lymphoma": 0.27531880140304565, "leukemia hematology": 0.2685849964618683, "hematologic": 0.26745283603668213, "cll": 0.26713916659355164, "chronic": 0.2647603452205658}, "8": {"safe effective": 0.4940258860588074, "more effective": 0.47234463691711426, "safety and efficacy": 0.4643074572086334, "efficacy": 0.46123191714286804, "efficacy and safety": 0.4577811062335968, "effective": 0.4507299065589905, "side effects": 0.4242914319038391, "effects": 0.36577409505844116, "effect": 0.36150896549224854, "refractory cll": 0.32201308012008667, "btk inhibitors": 0.312694787979126, "btk inhibitor": 0.3044344484806061, "acalabrutinib demonstrates": 0.3013521730899811, "venetoclax obinutuzumab": 0.29080653190612793, "chronic lymphocytic": 0.27665573358535767, "impact": 0.2710230350494385, "covid vaccine": 0.2663741111755371, "cll": 0.2596265375614166, "btk inhibition": 0.2594375014305115, "refractory chronic": 0.2578172981739044, "cll sll": 0.2521577775478363, "pi inhibitors": 0.249989852309227, "active": 0.23939287662506104, "positive results": 0.23026010394096375, "plus obinutuzumab": 0.22498714923858643, "umbralisib ublituximab": 0.22489222884178162, "chronic": 0.2223953902721405, "lymphocytic leukaemia": 0.22199366986751556, "plus venetoclax": 0.22159115970134735, "lymphocytic": 0.2185000330209732, "inhibitor": 0.21770760416984558, "inhibitors": 0.21712598204612732, "lymphocyte count": 0.21664464473724365, "patients with chronic": 0.2165948748588562, "cirmtuzumab": 0.20899255573749542, "lymphocytic leukemia": 0.20575721561908722, "lymphocyte": 0.2027300000190735, "follicular lymphoma": 0.2010498344898224, "drug": 0.20030823349952698, "ibrutinib plus": 0.1996174156665802, "survival benefit": 0.19958820939064026, "benefit": 0.19914498925209045, "venetoclax": 0.19886857271194458, "well tolerated": 0.19875305891036987, "fully vaccinated": 0.19388246536254883, "acalabrutinib shows": 0.19246891140937805, "lymphocytes": 0.18940341472625732, "venetoclax based": 0.18740251660346985, "small lymphocytic": 0.18663564324378967, "taking": 0.1863962709903717}, "9": {"cancer therapy": 0.4086693227291107, "lymphocytic leukaemia": 0.3876200318336487, "leukemia hematology": 0.36984673142433167, "lymphocytic leukemia": 0.3598589301109314, "tumor lysis": 0.35797321796417236, "chronic lymphocytic": 0.3410642445087433, "chemotherapy": 0.33838775753974915, "blood cancer": 0.3365423083305359, "cancer network": 0.33388257026672363, "chemotherapy free": 0.3260815739631653, "hematologic malignancies": 0.3254246115684509, "blood cancers": 0.32348182797431946, "cancer": 0.3230268061161041, "covid vaccine": 0.3220541477203369, "immunotherapy": 0.3205677568912506, "cell therapy": 0.3176618218421936, "hematologist oncologist": 0.3113464117050171, "leukaemia": 0.3087742328643799, "leukemia": 0.30413931608200073, "cancer center": 0.30133169889450073, "follicular lymphoma": 0.29618120193481445, "cancers": 0.2947375178337097, "newly diagnosed": 0.29361093044281006, "tumor": 0.2915293872356415, "hematology advisor": 0.2895294725894928, "lymphocyte count": 0.28470277786254883, "lymphocytic": 0.28302615880966187, "cancer survivors": 0.27805233001708984, "lymphocyte": 0.27456963062286377, "lymphocytes": 0.2733236253261566, "swollen lymph": 0.2691522240638733, "cell malignancies": 0.26791250705718994, "small lymphocytic": 0.2672273516654968, "hematologist": 0.2656838297843933, "was diagnosed": 0.26528656482696533, "hematology": 0.2629218101501465, "hematologic": 0.2615831196308136, "tg therapeutics": 0.2593950033187866, "fully vaccinated": 0.25602877140045166, "disease progression": 0.25540611147880554, "clinical trial": 0.25495386123657227, "patients with chronic": 0.254641056060791, "oncologist": 0.25379276275634766, "clinical trials": 0.24903815984725952, "therapeutics announces": 0.24829065799713135, "vaccine": 0.24334290623664856, "vaccinated": 0.24187776446342468, "vaccination": 0.24056586623191833, "combination therapies": 0.2400866448879242, "enlarged lymph": 0.23906490206718445}, "10": {"response rate": 0.42134758830070496, "response rates": 0.41376006603240967, "immune response": 0.3729252815246582, "btk inhibitors": 0.35016128420829773, "refractory cll": 0.3350675106048584, "btk inhibitor": 0.33406805992126465, "venetoclax obinutuzumab": 0.3330894410610199, "response": 0.330814927816391, "responses": 0.3257651925086975, "high": 0.31697356700897217, "umbralisib ublituximab": 0.3042944073677063, "acalabrutinib demonstrates": 0.3042409420013428, "reply": 0.30396538972854614, "btk inhibition": 0.2997346520423889, "durable responses": 0.29767200350761414, "higher": 0.29229915142059326, "chronic lymphocytic": 0.2909059524536133, "your reply": 0.2812381982803345, "high risk": 0.2793506979942322, "pi inhibitors": 0.27527695894241333, "plus venetoclax": 0.26539090275764465, "lymphocytic": 0.2646510899066925, "refractory chronic": 0.26243528723716736, "enlarged lymph": 0.2614436149597168, "lymphocytic leukaemia": 0.25787869095802307, "relapsed refractory": 0.25235357880592346, "plus obinutuzumab": 0.2521844804286957, "cll": 0.2519027590751648, "lymphocytic leukemia": 0.24925068020820618, "lymphocyte": 0.24293360114097595, "covid vaccine": 0.24170327186584473, "follicular lymphoma": 0.24139504134655, "venetoclax": 0.241385817527771, "lymphocyte count": 0.24119819700717926, "inhibitors": 0.24063031375408173, "answer": 0.23674629628658295, "small lymphocytic": 0.2359352707862854, "lymphocytes": 0.23314091563224792, "inhibitor": 0.22982390224933624, "ibrutinib plus": 0.22341588139533997, "low": 0.2228437066078186, "venetoclax based": 0.22242452204227448, "cirmtuzumab": 0.219835102558136, "cll sll": 0.21784794330596924, "leukemia": 0.21720829606056213, "swollen lymph": 0.21596375107765198, "rate": 0.2094130516052246, "acalabrutinib": 0.205458402633667, "antibodies": 0.20440590381622314, "acalabrutinib shows": 0.20438498258590698}, "11": {"prognostic factors": 0.4680059552192688, "prognostic": 0.41231027245521545, "predict": 0.3829196095466614, "genetic": 0.35368725657463074, "disease progression": 0.34721359610557556, "chronic lymphocytic": 0.33765265345573425, "treatment paradigm": 0.3175704777240753, "leukemia hematology": 0.31667575240135193, "mutations": 0.3145138919353485, "refractory cll": 0.312837690114975, "patients with chronic": 0.3109111487865448, "mutation": 0.30769795179367065, "refractory chronic": 0.3016337752342224, "hematologic malignancies": 0.29926392436027527, "was diagnosed": 0.2991570234298706, "diagnosis": 0.2941184937953949, "cell therapy": 0.2937749922275543, "previously treated": 0.2928624749183655, "diagnosed": 0.29265713691711426, "hematology advisor": 0.2916417121887207, "lymphocytic leukaemia": 0.29134416580200195, "hematologist oncologist": 0.2872406840324402, "hematology": 0.28719761967658997, "gene": 0.2854611575603485, "syndrome": 0.2837468981742859, "flow cytometry": 0.2790098190307617, "clinical trial": 0.27743834257125854, "newly diagnosed": 0.27734166383743286, "lymphocytic leukemia": 0.27549126744270325, "lymphocyte count": 0.27328798174858093, "clinical trials": 0.26980412006378174, "hematologist": 0.2679102122783661, "chronic": 0.2646244466304779, "covid vaccine": 0.26310932636260986, "chemotherapy": 0.26136350631713867, "chemotherapy free": 0.26124298572540283, "therapeutics announces": 0.25873154401779175, "oncology": 0.258675754070282, "cancer therapy": 0.2574082314968109, "cell transplant": 0.2567940950393677, "cll": 0.25430989265441895, "oncologist": 0.2540692389011383, "targeted therapies": 0.2538698613643646, "hematologic": 0.2533720135688782, "clinical": 0.25292590260505676, "lymphocytic": 0.2516057789325714, "cell malignancies": 0.25127270817756653, "tg therapeutics": 0.2506454885005951, "treatment naive": 0.24806761741638184, "treatment options": 0.24486923217773438}, "12": {"fda approval": 0.49609726667404175, "fda approves": 0.4858853220939636, "approved": 0.3440095782279968, "venetoclax obinutuzumab": 0.3313896954059601, "refractory cll": 0.33137840032577515, "approval": 0.32273128628730774, "follicular lymphoma": 0.3215002119541168, "chronic lymphocytic": 0.31751906871795654, "fda grants": 0.3163367807865143, "btk inhibitors": 0.3128182291984558, "btk inhibitor": 0.3097588121891022, "acalabrutinib demonstrates": 0.30439186096191406, "approves": 0.3034324645996094, "covid vaccine": 0.30151480436325073, "lymphocytic leukaemia": 0.2950234115123749, "btk inhibition": 0.29256194829940796, "lymphocytic": 0.2768232822418213, "lymphocyte count": 0.27617329359054565, "lymphocytic leukemia": 0.27515512704849243, "venetoclax based": 0.2720315754413605, "umbralisib ublituximab": 0.27102747559547424, "swollen lymph": 0.26441019773483276, "lymphocyte": 0.2608417868614197, "cll sll": 0.25604644417762756, "enlarged lymph": 0.2538113296031952, "cll": 0.2537597417831421, "lymphocytes": 0.2474198043346405, "lymph nodes": 0.24442966282367706, "pi inhibitors": 0.2410763055086136, "refractory chronic": 0.2403598129749298, "lymphoma": 0.2331620752811432, "small lymphocytic": 0.23224134743213654, "obinutuzumab combo": 0.22363215684890747, "previously treated": 0.22323618829250336, "drug": 0.21804912388324738, "taking": 0.21786758303642273, "therapeutics announces": 0.21783794462680817, "fully vaccinated": 0.2170141339302063, "lymph": 0.2158394753932953, "given": 0.2122916877269745, "fda": 0.21011458337306976, "improves pfs": 0.20968246459960938, "plus obinutuzumab": 0.20932206511497498, "venetoclax": 0.20899218320846558, "plus venetoclax": 0.20891892910003662, "well tolerated": 0.20831866562366486, "fcr": 0.20805856585502625, "patients with chronic": 0.206983745098114, "prolongs pfs": 0.20641903579235077, "relapsed refractory": 0.20328916609287262}, "13": {"high risk": 0.5420590043067932, "risk": 0.37851226329803467, "patients with chronic": 0.3523375391960144, "lymphocytic leukaemia": 0.321962833404541, "high": 0.31516164541244507, "chronic lymphocytic": 0.3105480968952179, "covid vaccine": 0.3012663722038269, "higher": 0.286832332611084, "lymphocytic leukemia": 0.2858729362487793, "leukemia": 0.2843872010707855, "hematologic malignancies": 0.28145885467529297, "leukaemia": 0.2770552337169647, "disease progression": 0.27282243967056274, "leukemia hematology": 0.2696149945259094, "btk inhibitors": 0.2660720944404602, "refractory cll": 0.26163753867149353, "refractory chronic": 0.25437724590301514, "btk inhibitor": 0.24763236939907074, "disease": 0.24693340063095093, "enlarged lymph": 0.24678514897823334, "chronic": 0.24231848120689392, "older patients": 0.24182045459747314, "venetoclax obinutuzumab": 0.24118024110794067, "blood cancers": 0.24014374613761902, "hematologic": 0.23798267543315887, "blood cancer": 0.23771874606609344, "lymphocytic": 0.23632267117500305, "cll": 0.2315671145915985, "btk inhibition": 0.22785083949565887, "lymphocyte count": 0.22726522386074066, "umbralisib ublituximab": 0.22689659893512726, "plus venetoclax": 0.22504568099975586, "lymphocyte": 0.22309809923171997, "lymphocytes": 0.2223852127790451, "cancer": 0.21944642066955566, "small lymphocytic": 0.21830692887306213, "cancers": 0.21525074541568756, "follicular lymphoma": 0.2144530713558197, "side effects": 0.21226413547992706, "toxicity": 0.21115556359291077, "swollen lymph": 0.2062174379825592, "fully vaccinated": 0.20588980615139008, "cancer survivors": 0.20570895075798035, "immunotherapy": 0.2031952440738678, "syndrome": 0.2014789879322052, "younger patients": 0.20076557993888855, "tumor lysis": 0.20009678602218628, "cancer center": 0.1985742747783661, "severe": 0.1983952671289444, "infection": 0.1964264065027237}, "14": {"older patients": 0.5376873016357422, "patients with chronic": 0.5217925310134888, "elderly patients": 0.4981389045715332, "younger patients": 0.4501989483833313, "chronic lymphocytic": 0.3991753160953522, "refractory chronic": 0.35129547119140625, "patients": 0.3489255905151367, "elderly": 0.341048002243042, "chronic": 0.33948731422424316, "previously treated": 0.33898982405662537, "previously untreated": 0.33039841055870056, "lymphocytic leukaemia": 0.3296048045158386, "immunotherapy": 0.3077070713043213, "disease progression": 0.30349716544151306, "lymphocytic leukemia": 0.295461505651474, "treatment naive": 0.29392245411872864, "covid vaccine": 0.29299601912498474, "patient": 0.289729505777359, "older": 0.2891645133495331, "old": 0.28049135208129883, "leukaemia": 0.2782280743122101, "tg therapeutics": 0.27797120809555054, "combination therapies": 0.2750634551048279, "leukemia": 0.27261388301849365, "leukemia hematology": 0.26999858021736145, "treatment": 0.26936304569244385, "cure": 0.26815441250801086, "cell therapy": 0.26753145456314087, "btk inhibitors": 0.26380133628845215, "chemotherapy free": 0.2636837065219879, "disease": 0.26209089159965515, "combination therapy": 0.26208293437957764, "hematologic malignancies": 0.26141420006752014, "treatment paradigm": 0.26104581356048584, "lymphocytic": 0.2602032721042633, "refractory cll": 0.25778311491012573, "follicular lymphoma": 0.252199649810791, "clinical": 0.2516776919364929, "btk inhibitor": 0.24964465200901031, "treatments": 0.24963036179542542, "cancer therapy": 0.24675767123699188, "treated": 0.2411983609199524, "lymphocyte": 0.24104291200637817, "standard of care": 0.24040964245796204, "lymphocyte count": 0.23861142992973328, "targeted therapies": 0.23788848519325256, "hematologic": 0.23757751286029816, "ibrutinib plus": 0.2368324100971222, "clinical trials": 0.23623107373714447, "clinical trial": 0.23607978224754333}, "15": {"first line": 0.48031648993492126, "venetoclax obinutuzumab": 0.33653584122657776, "second line": 0.33232933282852173, "previously treated": 0.33100438117980957, "venetoclax based": 0.319088339805603, "first": 0.3080209493637085, "front line": 0.29317671060562134, "previously untreated": 0.2865462899208069, "venetoclax": 0.28500959277153015, "line": 0.27522850036621094, "plus venetoclax": 0.2734781503677368, "chronic lymphocytic": 0.2730620503425598, "covid vaccine": 0.2720949351787567, "chemotherapy free": 0.2678666114807129, "refractory cll": 0.263708233833313, "cell therapy": 0.2606874704360962, "frontline": 0.258126437664032, "early stage": 0.25470811128616333, "lymphocytic leukaemia": 0.2529594898223877, "treatment paradigm": 0.2487928867340088, "lymphocytic": 0.24564456939697266, "follicular lymphoma": 0.24285945296287537, "treatment naive": 0.24008411169052124, "lymphocytic leukemia": 0.23935233056545258, "treatment": 0.23638270795345306, "combination therapy": 0.23530104756355286, "targeted therapies": 0.23201817274093628, "tg therapeutics": 0.23096609115600586, "chemotherapy": 0.2303771823644638, "lymphocyte": 0.23022249341011047, "immunotherapy": 0.22979429364204407, "primary": 0.22882838547229767, "targeted therapy": 0.22462016344070435, "combination therapies": 0.22264425456523895, "treatment options": 0.21840572357177734, "cancer therapy": 0.21754775941371918, "leukemia hematology": 0.21669436991214752, "monotherapy": 0.21530377864837646, "lymphocytes": 0.2140626162290573, "therapeutics announces": 0.21343445777893066, "prior": 0.21085768938064575, "treatments": 0.2107694149017334, "lymph nodes": 0.2090045064687729, "small lymphocytic": 0.20896883308887482, "lymphocyte count": 0.2087581753730774, "btk inhibitors": 0.20847445726394653, "btk inhibitor": 0.20831938087940216, "before": 0.20820356905460358, "cll": 0.20702660083770752, "cll sll": 0.205585777759552}}